178 related articles for article (PubMed ID: 38614937)
1. Secondary syphilis occurring under anti-CD20 therapy: risks, progression and approach.
Garbers LAFM; Haes TM; Silva Souza CD
An Bras Dermatol; 2024; 99(4):632-634. PubMed ID: 38614937
[No Abstract] [Full Text] [Related]
2. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.
Tallantyre EC; Whittam DH; Jolles S; Paling D; Constantinesecu C; Robertson NP; Jacob A
J Neurol; 2018 May; 265(5):1115-1122. PubMed ID: 29511864
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.
Sohani AR; Maurer MJ; Giri S; Pitcher B; Chadburn A; Said JW; Bartlett NL; Czuczman MS; Martin P; Rosenbaum CA; Jung SH; Leonard JP; Cheson BD; Hsi ED
Am J Surg Pathol; 2021 Mar; 45(3):384-393. PubMed ID: 33136585
[TBL] [Abstract][Full Text] [Related]
4. Serological diagnosis of secondary syphilis in a Rituximab-treated patient: an emerging diagnostic challenge?
Lefeuvre C; Croué A; Abgueguen P; Letzelter M; Ducancelle A; Grange P; Benhaddou N; Dupin N; Le Guillou-Guillemette H; Le Clec'h C
J Eur Acad Dermatol Venereol; 2021 May; 35(5):e350-e352. PubMed ID: 33462864
[No Abstract] [Full Text] [Related]
5. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20
Luo C; Wu G; Huang X; Ma Y; Zhang Y; Song Q; Xie M; Sun Y; Huang Y; Huang Z; Hou Y; Xu S; Chen J; Li X
Sci Rep; 2021 Feb; 11(1):3255. PubMed ID: 33547368
[TBL] [Abstract][Full Text] [Related]
7. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.
Hunt CM; Beste LA; Lowy E; Suzuki A; Moylan CA; Tillmann HL; Ioannou GN; Lim JK; Kelley MJ; Provenzale D
World J Gastroenterol; 2016 May; 22(19):4732-40. PubMed ID: 27217704
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.
Boyer-Suavet S; Andreani M; Lateb M; Savenkoff B; Brglez V; Benzaken S; Bernard G; Nachman PH; Esnault V; Seitz-Polski B
Front Immunol; 2019; 10():3069. PubMed ID: 31998325
[TBL] [Abstract][Full Text] [Related]
9. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
10. Protracted SARS-CoV-2 pneumonia with rituximab treatment: About two cases.
Gerber V; Velay A; Boehn L; Solis M; Kaeuffer C; Rougier E; Ursenbach A; Hansmann Y; Lefebvre N; Danion F; Ruch Y
J Med Virol; 2021 Jul; 93(7):4141-4144. PubMed ID: 33666242
[No Abstract] [Full Text] [Related]
11. A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).
Zent CS; Victoria Wang X; Ketterling RP; Hanson CA; Libby EN; Barrientos JC; Call TG; Chang JE; Liu JJ; Calvo AR; Lazarus HM; Rowe JM; Luger SM; Litzow MR; Tallman MS
Am J Hematol; 2016 Mar; 91(3):308-12. PubMed ID: 26662208
[TBL] [Abstract][Full Text] [Related]
12. A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
Izutsu K; Kinoshita T; Takizawa J; Fukuhara S; Yamamoto G; Ohashi Y; Suzumiya J; Tobinai K
Jpn J Clin Oncol; 2021 Mar; 51(3):408-415. PubMed ID: 33244584
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.
Iwata S; Saito K; Hirata S; Ohkubo N; Nakayamada S; Nakano K; Hanami K; Kubo S; Miyagawa I; Yoshikawa M; Miyazaki Y; Yoshinari H; Tanaka Y
Lupus; 2018 Apr; 27(5):802-811. PubMed ID: 29308726
[TBL] [Abstract][Full Text] [Related]
14. Current role of rituximab in systemic lupus erythematosus.
Mok CC
Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
[TBL] [Abstract][Full Text] [Related]
15. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera
Sharman JP; Liberati AM; Ishizawa K; Khan T; Robbins J; Alcasid A; Rosenberg JA; Aurer I
BioDrugs; 2020 Apr; 34(2):171-181. PubMed ID: 31820339
[TBL] [Abstract][Full Text] [Related]
16. Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.
Rogers LM; Mott SL; Smith BJ; Link BK; Sahin D; Weiner GJ
Clin Cancer Res; 2017 Feb; 23(4):954-961. PubMed ID: 27528699
[No Abstract] [Full Text] [Related]
17. Autoimmune Sequelae Following Rituximab Therapy: A Review of the Literature and Potential Immunologic Mechanisms.
Kersh AE; Feldman RJ
J Clin Rheumatol; 2018 Dec; 24(8):427-435. PubMed ID: 29561469
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for nephrotic syndrome in children.
Iijima K; Sako M; Nozu K
Clin Exp Nephrol; 2017 Apr; 21(2):193-202. PubMed ID: 27422620
[TBL] [Abstract][Full Text] [Related]
19. Secondary syphilis occurring under anti-TNFalpha therapy.
Bories-Haffner C; Buche S; Paccou J
Joint Bone Spine; 2010 Jul; 77(4):364-5. PubMed ID: 20452802
[TBL] [Abstract][Full Text] [Related]
20. Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome.
Eberle FC; Holstein J; Scheu A; Fend F; Yazdi AS
J Dtsch Dermatol Ges; 2017 Mar; 15(3):319-323. PubMed ID: 28177583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]